Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy

Autor: Lutian Yao, Jiawei Lu, Leilei Zhong, Yulong Wei, Tao Gui, Luqiang Wang, Jaimo Ahn, Joel D Boerckel, Danielle Rux, Christina Mundy, Ling Qin, Maurizio Pacifici

Publikováno v: eLife, Vol 12 (2023)

Insufficient bone fracture repair represents a major clinical and societal burden and novel strategies are needed to address it. Our data reveal that the transforming growth factor-β superfamily member Activin A became very abundant during mouse and

Externí odkaz: https://doaj.org/article/e2afbc82a06e4e92a58094be629da842

P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Autor: Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Cindy Xu, Carmelo Carlo-Stella

Publikováno v: HemaSphere, Vol 7, p e402511c (2023)

Externí odkaz: https://doaj.org/article/979bb44e11154e29b5cffd1614fbdd2a

Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment

Autor: Leilei Zhong, Lutian Yao, Robert J Tower, Yulong Wei, Zhen Miao, Jihwan Park, Rojesh Shrestha, Luqiang Wang, Wei Yu, Nicholas Holdreith, Xiaobin Huang, Yejia Zhang, Wei Tong, Yanqing Gong, Jaimo Ahn, Katalin Susztak, Nathanial Dyment, Mingyao Li, Fanxin Long, Chider Chen, Patrick Seale, Ling Qin

Publikováno v: eLife, Vol 9 (2020)

Bone marrow mesenchymal lineage cells are a heterogeneous cell population involved in bone homeostasis and diseases such as osteoporosis. While it is long postulated that they originate from mesenchymal stem cells, the true identity of progenitors an

Externí odkaz: https://doaj.org/article/e1bde3bf4480496eb8cd45466e510294

Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Autor: Laura Liao, Brad S. Kahl, John Radford, Xiaolei Zhou, David Ungar, Ari Gnanasakthy, Rafael E. Curiel, Luqiang Wang, Lei Chen, Alexander I. Spira

Publikováno v: Spira, A, Zhou, X, Chen, L, Gnanasakthy, A, Wang, L, Ungar, D, Curiel, R, Liao, L, Radford, J & Kahl, B 2021, ' Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma ', Clinical Lymphoma, Myeloma and Leukemia . https://doi.org/10.1016/j.clml.2021.09.001

Background Loncastuximab tesirine has shown antitumor activity with an acceptable toxicity profile in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were relapsed or refractory after ≥2 prior therapies, including act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6180cbd7257cb70367a8590cb2412e
https://doi.org/10.1016/j.clml.2021.09.001

Short Cyclic Regimen With Parathyroid Hormone ( PTH ) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats

Autor: Wei‐Ju Tseng, Wonsae Lee, Hongbo Zhao, Yang Liu, Wenzheng Wang, Chantal MJ Bakker, Yihan Li, Carlos Osuna, Wei Tong, Luqiang Wang, Xiaoyuan Ma, Ling Qin, X Sherry Liu

Publikováno v: J Bone Miner Res

Despite the potent effect of intermittent parathyroid hormone (PTH) treatment on promoting new bone formation, bone mineral density (BMD) rapidly decreases upon discontinuation of PTH administration. To uncover the mechanisms behind this adverse phen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::124b1afc3e8278827a1e29e21d3c0de6
https://doi.org/10.1002/jbmr.4495